Ny jobb for Sigve Brekke, dobbel Aker og ny BerGenBio-sjef om viktig kreftstudie

Olav Hellebø har vært i biotech og pharma i en årrekke, og i november kom han inn som ny sjef i BerGenBio. Allerede før sommeren venter de resultatene fra studioen av en inhibator til førstelinjebruk mot lungekreft. Vi ser også nærmere på dagens nyheter rundt Aker-systemet, statens nedsalg, Kongsberg Gruppens omorganisering og Sigve Brekkes nye jobb i Bangkok. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Jan 9, 2025

Embed this episode

Attribution link and audio player

Ready to play

Ny jobb for Sigve Brekke, dobbel Aker og ny BerGenBio-sjef om viktig kreftstudie

0:00 17:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Børsmorgen & Økonominyhetene?

This episode is 17 minutes long.

When was this Børsmorgen & Økonominyhetene episode published?

This episode was published on January 9, 2025.

Can I download this Børsmorgen & Økonominyhetene episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!